用于治疗实体瘤的单克隆抗体和Fc片段。
Monoclonal antibodies and Fc fragments for treating solid tumors.
作者信息
Eisenbeis Andrea M, Grau Stefan J
机构信息
Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany.
出版信息
Biologics. 2012;6:13-20. doi: 10.2147/BTT.S19955. Epub 2012 Jan 5.
Abstract
Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use of monoclonal antibodies and Fc fragments in various fields in medicine. In this context, a rapidly growing number of these substances have also emerged in the field of oncology. This review will summarize the currently approved monoclonal antibodies used for the treatment of solid tumors with a focus on their clinical application, biological background, and currently ongoing trials.
摘要
生物技术的进步、对病理生理过程的更深入理解以及越来越多分子标志物的发现，促进了单克隆抗体和Fc片段在医学各个领域的应用。在此背景下，肿瘤学领域也出现了数量迅速增长的这类物质。本综述将总结目前已获批用于治疗实体瘤的单克隆抗体，重点关注其临床应用、生物学背景以及当前正在进行的试验。
相似文献
1
Monoclonal antibodies and Fc fragments for treating solid tumors.用于治疗实体瘤的单克隆抗体和Fc片段。
Biologics. 2012;6:13-20. doi: 10.2147/BTT.S19955. Epub 2012 Jan 5.
2
Enhanced Natural Killer Cell Immunotherapy by Rationally Assembling Fc Fragments of Antibodies onto Tumor Membranes.通过将抗体的 Fc 片段合理组装到肿瘤膜上增强自然杀伤细胞免疫疗法。
Adv Mater. 2019 Feb;31(6):e1804395. doi: 10.1002/adma.201804395. Epub 2018 Dec 14.
3
Approved monoclonal antibodies for cancer therapy.已批准用于癌症治疗的单克隆抗体。
Expert Opin Biol Ther. 2008 Aug;8(8):1151-8. doi: 10.1517/14712598.8.8.1151.
4
Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations.抗体片段作为癌症治疗的潜在生物制药：成功与局限。
Curr Med Chem. 2019;26(3):396-426. doi: 10.2174/0929867324666170817152554.
5
Endometrial cancer: Molecular markers and management of advanced stage disease.子宫内膜癌：晚期疾病的分子标志物和治疗管理。
Gynecol Oncol. 2018 Sep;150(3):569-580. doi: 10.1016/j.ygyno.2018.05.015. Epub 2018 May 27.
6
Therapeutic Antibodies in Cancer Therapy.癌症治疗中的治疗性抗体。
Adv Exp Med Biol. 2016;917:95-120. doi: 10.1007/978-3-319-32805-8_6.
8
Monoclonal antibodies in oncology therapeutics: present and future indications.肿瘤治疗中的单克隆抗体：当前和未来的适应证。
Expert Opin Biol Ther. 2013 Feb;13(2):269-82. doi: 10.1517/14712598.2012.758705. Epub 2013 Jan 4.
9
The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.治疗性抗体的“少即是多”：去岩藻糖基化的抗肿瘤抗体增强抗体依赖的细胞毒性。
MAbs. 2018 Jul;10(5):693-711. doi: 10.1080/19420862.2018.1466767.
10
Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.肿瘤治疗性抗体研发中的药物遗传学与药物基因组学
Biotechniques. 2005 Oct;39(4):565-8.
引用本文的文献
1
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.三期 HERITAGE 研究的最终总生存分析显示，曲妥珠单抗-dkst 与曲妥珠单抗在 HER2 阳性转移性乳腺癌中的疗效相当。
Breast Cancer Res Treat. 2021 Jul;188(2):369-377. doi: 10.1007/s10549-021-06197-5. Epub 2021 Jun 14.
2
A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.一项曲妥珠单抗生物类似药 MYL-1401O 与欧盟曲妥珠单抗和美国曲妥珠单抗的药代动力学 1 期生物等效性研究。
Br J Clin Pharmacol. 2018 Oct;84(10):2336-2343. doi: 10.1111/bcp.13689. Epub 2018 Jul 31.
本文引用的文献
1
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.在铂类化疗失败后复发或转移性头颈部鳞状细胞癌患者中，泽鲁妥珠单抗联合最佳支持治疗与最佳支持治疗相比：一项开放标签、随机 3 期试验。
Lancet Oncol. 2011 Apr;12(4):333-43. doi: 10.1016/S1470-2045(11)70034-1. Epub 2011 Mar 4.
2
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.一项比较帕尼单抗联合氟尿嘧啶、亚叶酸钙和伊立替康（FOLFIRI）与单独 FOLFIRI 二线治疗转移性结直肠癌患者的随机 III 期研究。
J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.
3
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
4
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients.一项在转移性肾细胞癌患者中使用单克隆抗体 cG250（RENCAREX®）和干扰素-α-2a 的临床 I/II 期试验。
World J Urol. 2011 Feb;29(1):121-6. doi: 10.1007/s00345-010-0570-2. Epub 2010 May 30.
5
Catumaxomab: clinical development and future directions.卡妥索单抗：临床开发及未来方向。
MAbs. 2010 Mar-Apr;2(2):129-36. doi: 10.4161/mabs.2.2.11221.
6
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.皮肤毒性评价方案（STEPP）与帕尼单抗（panitumumab）：一项Ⅱ期、开放性、随机试验，评估在转移性结直肠癌患者中预先皮肤处理方案对皮肤毒性和生活质量的影响。
J Clin Oncol. 2010 Mar 10;28(8):1351-7. doi: 10.1200/JCO.2008.21.7828. Epub 2010 Feb 8.
7
Cetuximab: from bench to bedside.西妥昔单抗：从实验室到临床。
Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. doi: 10.2174/156800910790980241.
8
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.Tremelimumab（CP-675,206）治疗晚期难治性或复发性黑色素瘤的 II 期临床试验。
Clin Cancer Res. 2010 Feb 1;16(3):1042-8. doi: 10.1158/1078-0432.CCR-09-2033. Epub 2010 Jan 19.
9
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.曲妥珠单抗和帕妥珠单抗联合治疗对 HER2 阳性人源异种移植肿瘤模型的抗肿瘤活性显著增强。
Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597.
10
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.放疗联合西妥昔单抗治疗局部晚期头颈部癌：III 期随机试验的 5 年生存数据，以及西妥昔单抗诱导皮疹与生存的关系。
Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10.
Zotero 插件